Utilizacion del ECMO en el distress respiratorio. Presentacion de sesiones cientificas del departamento de cirugia cardiaca de la clinica universidad de navarra
ECMO provides cardiopulmonary support by oxygenating blood and supporting circulation outside the body. The history of ECMO began in the 1930s with experiments in extracorporeal circulation and progressed to successful use in humans in the 1950s. Indications for ECMO include cardiac and pulmonary failure. Contraindications include advanced organ failure or inability to anticoagulate. Cannulation techniques include central cannulation through major blood vessels or peripheral cannulation through the neck or groin.
This document provides an overview of extracorporeal membrane oxygenation (ECMO) in 3 parts. It discusses the history and evolution of ECMO from its origins in the 1950s to more modern applications. ECMO can be used in veno-venous or veno-arterial modes, with veno-venous providing oxygenation support for lung failure and veno-arterial providing both oxygenation and circulatory support. The document outlines common indications for ECMO and considerations for cannulation approaches and placements. It also previews topics that will be covered in more depth in the second part such as monitoring, complications, and guidelines.
- ECMO is a form of extracorporeal life support that involves removing blood from the body, oxygenating it using an artificial lung, then returning it to circulate oxygenated blood through the body.
- It was first developed in the 1950s and saw its first successful use in 1971. It is now commonly used to support patients with severe cardiac and/or respiratory failure.
- There are two main types - venoarterial (VA) ECMO which supports cardiac function and venovenous (VV) ECMO which supports respiratory function. Indications, complications, and outcomes were discussed.
1. The document describes a case of a 28-year-old female with cyanotic congenital heart disease who underwent an arterial switch operation with integrated ECMO support.
2. ECMO is a form of extracorporeal life support used for both cardiac and respiratory failure in adults. It involves pumping blood out of the body to an artificial lung for gas exchange before returning it to circulation.
3. The key components of an ECMO circuit include a blood pump, membrane oxygenator, tubing, heat exchanger, and monitoring equipment. Proper anticoagulation and flow rates are important for safety and effectiveness.
This document provides an overview of extracorporeal membrane oxygenation (ECMO) including its definition, history, components, configurations, physiology, indications, and complications. ECMO temporarily replaces or supports the cardiopulmonary system by extracting blood, oxygenating it through an artificial lung, then returning it to circulation. Key points include:
- ECMO was developed in the 1960s-70s and can support heart and/or lung function for weeks.
- The circuit includes cannulae, a pump, oxygenator, and controller. Configurations include venovenous (lung support) and venoarterial (heart and lung support).
- ECMO settings impact oxygen delivery and carbon dioxide
This document discusses extracorporeal membrane oxygenation (ECMO) as a treatment for severe acute respiratory distress syndrome (ARDS). It provides details on:
1. How ECMO works by using an external circuit to oxygenate blood and remove carbon dioxide before returning it to the body.
2. The types of ECMO (veno-venous and veno-arterial) and their indications.
3. The process of ECMO, including patient care focused on end organ perfusion to prevent further injury and improve function.
4. Complications of ECMO like bleeding, infections, and mechanical issues.
5. Considerations for when to initiate ECMO based on oxygenation levels
ECMO, DEFINITION, ETIOLOGY, INDICATION, CONTRAINDICATION, TYPES OF ECMO, VENOVENOUS ECMO, VENO ARTERIAL ECMO, NURSING CARE OF PATIENT ON ECMO, WEANING FROM ECMO,
ECMO can be considered for partial or full cardiopulmonary support in cases of potentially reversible post-traumatic cardiopulmonary failure. Those with respiratory failure should be candidates for VV ECMO, while those with refractory cardiac dysfunction should receive VA ECMO. ECMO can improve oxygenation and circulation to limit complications like metabolic acidosis. Indications include severe lung injury from trauma leading to ARDS. Contraindications include unrecoverable injury or advanced organ dysfunction. While outcomes are best at high-volume centers, ECMO may allow time for injury recovery or organ donation in severe trauma.
This document discusses extracorporeal membrane oxygenation (ECMO) in adults. It describes the different types of ECMO (veno-arterial, veno-venous, arterio-venous), how the ECMO circuit works to facilitate gas exchange outside the body, clinical indications for its use including acute respiratory failure and cardiac support, complications, and transfusion guidelines for ECMO patients.
This document provides an overview of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for adults. It discusses how VA-ECMO can support patients with refractory cardiopulmonary failure for weeks. It describes the hemodynamics of cardiogenic shock and how VA-ECMO impacts pressure-volume loops. It outlines strategies to reduce pulmonary congestion on VA-ECMO and lists contraindications and predictors of mortality. It also discusses the use of ECMO for cardiac arrest (ECPR) and criteria for its use for refractory ventricular tachycardia or cardiogenic shock.
ECMO (extracorporeal membrane oxygenation) is a technique that uses pumps and a artificial lung to support heart and lung function. It can be used to support failing organs while allowing time for recovery or as a bridge to transplant. The history of ECMO began in the 1950s with the development of cardiopulmonary bypass and its use has expanded to support both children and adults with heart and lung failure. While intensive, ECMO can save lives that would otherwise be lost to critical illness.
This document discusses the use of ECMO (extracorporeal membrane oxygenation) after cardiac surgery. It outlines the indications for ECMO, including post-cardiotomy cardiogenic shock. Different cannulation strategies and their considerations are described. Monitoring patients on ECMO includes ensuring adequate oxygen delivery and preventing complications like bleeding, leg ischemia, and pulmonary edema. Myocardial stunning can lead to left ventricular overdistention, so decompression may be needed. Improving contractility may cause the harlequin phenomenon if lungs are not well ventilated. Outcome data shows a prevalence of 0.5-2.6% for post-cardiac surgery ECMO with in-hospital survival rates of
ECMO is a form of extracorporeal life support that involves removing blood from the body, oxygenating it using an artificial lung, then returning it to circulate in the body. It can be used for both cardiac and respiratory support for neonates and involves different configurations depending on whether support is needed for the heart, lungs, or both. Indications for ECMO include meconium aspiration syndrome, congenital diaphragmatic hernia, respiratory distress syndrome, and persistent pulmonary hypertension among others. Outcomes have improved over time with advances in technology and experience with the procedure.
Veno-arterial extracorporeal membrane oxygenation (VA ECMO) provides both respiratory and circulatory support for patients with heart and lung failure. It works by draining venous blood, oxygenating it, and returning it to the arterial system. The document discusses cannulation techniques and considerations for VA ECMO, as well as physiological effects and important monitoring parameters to optimize patient care and outcomes.
This document provides an overview of extracorporeal membrane oxygenation (ECMO), including its history, principles, components, indications, and complications. Some key points:
- ECMO is a form of extracorporeal life support that oxygenates blood and removes carbon dioxide outside of the body, then returns the blood to the patient. It has been used since the 1950s and is now standard treatment for some cardiac and respiratory conditions.
- The basic ECMO circuit includes a blood pump, membrane oxygenator, heat exchanger, cannulas, and tubing. There are various configurations depending on whether it is used for respiratory (VV ECMO) or cardiac (VA ECMO) support.
-
This document discusses extracorporeal membrane oxygenation (ECMO), which provides prolonged cardiopulmonary support. There are two main types of ECMO: venovenous (VV) ECMO, which provides respiratory support, and venoarterial (VA) ECMO, which provides both respiratory and hemodynamic support. The document outlines patient selection criteria and outcomes, complications, techniques for initiation and maintenance of ECMO, and considerations for weaning from and discontinuing ECMO support.
This document provides an overview of ECMO (extracorporeal membrane oxygenation) and E-CPR (extracorporeal cardiopulmonary resuscitation) at SCGH. It describes what ECMO is, the inclusion/exclusion criteria for its use, the equipment and staff required, and differences between a conventional and ECMO resuscitation. Key points include: ECMO provides temporary cardiac and/or respiratory support for patients failing maximal medical therapy; there are two types - VV and VA; VA ECMO/E-CPR is performed in the ED for cardiac arrest and provides both respiratory and hemodynamic support; and an ECMO resuscitation requires rapid cannulation and connection to an EC
This document discusses extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). ECMO provides cardiopulmonary support for critically ill patients, while CRRT manages fluid overload and acute kidney injury. The document outlines some of the technical considerations for combining ECMO and CRRT treatment, including using separate circuits or incorporating CRRT into the ECMO circuit. Some benefits of the combined treatment are managing fluid overload, electrolyte imbalances, and removing inflammatory cytokines. Early initiation of CRRT is recommended to improve outcomes in ECMO patients. Complications can include bleeding risks from anticoagulation and electrolyte disturbances.
1. basic aspects of physiology during ecmo supportNahas N
This document provides an overview of physiology during ECMO support. It discusses:
1) The basic principles of veno-arterial and veno-venous ECMO, which replace both heart and lung function or only lung function, respectively.
2) Oxygenation and carbon dioxide removal processes during ECMO, which rely on membrane gas exchange and blood flow/sweep gas flow rates.
3) Hemodynamic impacts that depend on the type of ECMO (veno-venous is neutral while veno-arterial reduces preload and increases afterload).
1. Extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) are important life support therapies used in intensive care units.
2. ECMO uses an external circuit to oxygenate blood and remove carbon dioxide, functioning as a bridge to recovery, transplant, or decision. CRRT slowly removes waste and fluid from the blood of patients with kidney failure or injury.
3. The document discusses the principles, indications, techniques, and complications of ECMO and CRRT, highlighting their roles in supporting critically ill patients with cardiac, respiratory, or renal issues.
ECMO is a form of extracorporeal life support used for patients with severe cardiac or respiratory failure. It works by removing blood from the body, oxygenating it, and returning it. The document discusses the history and development of ECMO, components of the ECMO circuit, modes of ECMO including veno-venous and veno-arterial, indications and contraindications for its use, complications, and criteria for weaning patients off of ECMO support.
This document provides an overview of extracorporeal membrane oxygenation (ECMO), including its history, modes, components, indications, contraindications, and complications. ECMO is an effective technique for providing emergency circulatory and respiratory support. It works by draining venous blood, oxygenating it through an artificial lung, and returning it to the circulation. There are two main modes - venoarterial (VA) ECMO which supports both heart and lung function, and venovenous (VV) ECMO which only supports lung function. Proper anticoagulation, volume management, and treatment of potential complications like bleeding, infection and circuit failures are important for safe ECMO management.
This document discusses extracorporeal membrane oxygenation (ECMO), including its indications, types (veno-arterial and veno-venous), management strategies, and the experience with ECMO at Heart Hospital. ECMO can be used as a bridge to recovery, decision-making, surgery, long-term devices like LVADs, or transplant. It involves draining blood from the body, removing carbon dioxide and adding oxygen through an external oxygenator before returning the blood. Management involves anticoagulation and monitoring various patient parameters. Complications can include bleeding, infection, and organ dysfunction. Criteria and protocols are discussed for weaning patients off ECMO support.
A brief yet comprehensive coverage of ICU role in ECMO cases. Presentation has been prepared in order to help ICU fellows and registrars to understand the importance of their role and to know necessary actions they have to take in case of need.
This document provides an overview of extracorporeal membrane oxygenation (ECMO), including its history, principles, components, indications, contraindications, mechanisms, and complications. ECMO is a form of extracorporeal life support that oxygenates a patient's blood and removes carbon dioxide before returning it to circulation. It is used as a bridge to recovery, decision, or transplant for patients with severe cardiac or respiratory failure. The document describes the various ECMO circuits and cannulation methods, as well as guidelines for initiation and monitoring of ECMO.
Veno-Arterial Ecmo (VA-ECMO) & Their basicGunalan M.M
VA ECMO stands for Venoarterial Extracorporeal Membrane Oxygenation. It's a life-saving medical procedure used in critical situations where the heart and lungs are unable to function adequately. VA ECMO involves diverting blood from the body, oxygenating it outside the body, and then returning it to the arterial system, effectively bypassing the heart and lungs. This allows time for the organs to rest and heal, supporting patients with severe cardiac or respiratory failure.
This workshop will outline the basic principles of extracorporeal life support made easy by key-experts in the field. During the course delegates will gain a good understanding of ECMO in the following areas: Theoretical concepts, basic physiology and pathophysiology, cardiac and respiratory support and monitoring, alarm settings and monitoring, role of cardiac ultrasound during ECMO, newest technologies, circuits and devices, practical hands-on sessions and simulations.
This document provides an overview of extracorporeal membrane oxygenation (ECMO). It describes what ECMO is, the differences between conventional cardiopulmonary bypass and ECMO, the types of ECMO circuits, ECMO flow calculations, cannulation techniques, indications for ECMO in neonates, pediatrics and adults, management of ECMO, and complications. The key points covered are: ECMO can provide both cardiac and respiratory support for longer durations than cardiopulmonary bypass; the two main types are venovenous and venoarterial ECMO; cannulation sites include femoral, axillary and internal jugular vessels; and indications and management vary between age groups.
This document discusses ECMO cannulation and potential pitfalls. It begins by outlining the personnel and equipment needed for ECMO, including pumps, oxygenators, and cannulas. It then describes the types of ECMO (VA and VV) and considerations for cannula choice and placement. Key steps in cannulation like imaging, vessel access and cannula fixation are covered. Management of the ECMO circuit and potential complications are also reviewed. Specifically, protocols for bleeding management, cannulation failures and malpositions are outlined to minimize risks. Overall, the document provides guidance on safely establishing ECMO support through cannulation and ongoing management.
VenovenousECMO physiology f extracorporeal life support where an external ar...bae sungjin
A form of extracorporeal life support where an external artificial circuit carries venous blood from the patient to a gas exchange device (oxygenator) where blood becomes enriched with oxygen and has carbon dioxide removed. This blood then re-enters the patient circulation.
1) The document provides information about extracorporeal membrane oxygenation (ECMO), including definitions, equipment, procedures, types (veno-venous and veno-arterial), management, and complications.
2) ECMO is a form of extracorporeal life support that involves removing blood from the body, oxygenating it in an artificial lung, and returning it to the circulation to support patients with severe heart and lung failure.
3) There are two main types - veno-venous ECMO which supports only the lungs, and veno-arterial ECMO which supports both the heart and lungs.
- Hemoptysis is the expectoration of blood from the respiratory tract below the level of the vocal cords. It can range from blood-streaked sputum to gross blood. It is classified as minor (<20mL/day), moderate (20-100mL/day), or massive (100-600mL/day).
- The bronchial arteries, which arise from the aorta, are responsible for 95% of hemoptysis cases as they have higher systemic pressure. The pulmonary arteries have lower pressure and carry only a small portion of cardiac output.
- Common causes of hemoptysis include tuberculosis, bronchiectasis, mycetoma, lung abscess, mitral stenosis, and
A 58-year-old male presented with cardiogenic shock after an anterolateral STEMI. He was started on VA ECMO support due to refractory shock and cardiac arrest. The patient developed left ventricular distension on ECMO due to non-ejection of the left ventricle. Potential causes were addressed with less invasive measures first, like reducing afterload and improving contractility, before considering more invasive interventions like an LV vent. Signs of potential cardiac recovery on ECMO include improved hemodynamics, echocardiogram findings, and reduced inotrope requirements. A trial reduction of ECMO flow can be done if these criteria are met to assess ability to wean from support.
Veno-venous extracorporeal membrane oxygenation (VV ECMO) is a life-saving therapy for severe respiratory failure. It involves using an external circuit to oxygenate and remove carbon dioxide from the blood, providing temporary support to the lungs. This allows the patient's lungs to rest and recover while maintaining oxygen delivery to the body. VV ECMO can be a bridge to recovery or lung transplantation for patients with acute respiratory distress syndrome (ARDS), pneumonia, or other conditions causing respiratory failure. It requires specialized equipment and expertise for cannulation, management, and monitoring.
#ecmo #vvecmo #heartlungmachine #vaecmo
CPB diverts blood flow away from the heart to an external circuit that oxygenates and returns the blood. It was first successfully used in 1953 to correct an atrial septal defect. The CPB circuit includes cannulas, a reservoir, oxygenator, heat exchanger, pump, and filters. It aims to replace heart and lung function during surgery. Key responsibilities of the anesthesiologist during CPB include acid-base management, anticoagulation, cardioplegia delivery, and cerebral protection.
This document summarizes New Zealand's national adult ECMO service based in Auckland City Hospital. ECMO uses an extracorporeal circuit to support the lungs and/or heart for extended periods. The national service began in 1993 and established a mobile ECMO retrieval team in 2005 to place and transport patients on ECMO anywhere in New Zealand. The mobile ECMO system was designed to be lightweight and portable to transport patients by road, fixed wing aircraft, or helicopter. During the 2009 H1N1 influenza pandemic, the service experienced a surge in ECMO cases and transports across New Zealand.
8. Capnography.ppt, the best and most improved versionSweetPotatoe1
Capnography measures carbon dioxide levels during exhalation and can provide information about a patient's ventilation and circulation. It is useful for confirming proper endotracheal tube placement, assessing CPR effectiveness, detecting return of spontaneous circulation during cardiac arrest, and optimizing ventilation rates in patients with traumatic brain injury. Changes in the shape of the capnogram waveform or the end-tidal carbon dioxide level can indicate conditions like asthma exacerbations, endotracheal tube obstruction, or inadequate chest compressions.
Similar to Ecmo en el distress respiratorio agudo otra herramienta para el intensivista (20)
Este documento describe los cursos de especialización de postgrado en enfermería ofrecidos por la Clínica Universidad de Navarra (CUN). Presenta siete cursos de especialización en áreas como oncohematología, psiquiatría, cuidados intensivos, cardiología y quirúrgica, con el objetivo de capacitar a los enfermeros con conocimientos especializados. Explica las metodologías docentes activas utilizadas y proporciona más información sobre los cursos.
Este documento resume la investigación actual sobre la válvula tricúspide. Describe que la insuficiencia tricúspide funcional es más compleja de lo que se pensaba, involucrando cambios en la forma y función del anillo valvular. También destaca la falta de consenso sobre cuándo reparar quirúrgicamente la válvula tricúspide.
El documento describe la regurgitación tricúspide en contexto. Explica la anatomía, las causas, la fisiopatología y la evaluación de la regurgitación tricúspide, incluidos los mecanismos, la cuantificación mediante ecocardiografía y la resonancia magnética. También analiza los factores de riesgo asociados con un grado postoperatorio más alto de regurgitación tricúspide y las indicaciones quirúrgicas.
Este documento resume la historia y uso del dispositivo ECMO (oxigenación por membrana extracorpórea) como una forma de asistencia cardiopulmonar barata y efectiva en situaciones de crisis. Describe brevemente el desarrollo del ECMO desde sus orígenes en la década de 1970 y sus usos actuales como puente hacia la decisión, el trasplante o la recuperación. Finalmente, presenta algunos resultados del uso del ECMO que muestran tasas de supervivencia del 50% en pacientes críticos.
Este documento presenta una guía sobre cómo realizar una búsqueda bibliográfica efectiva. Explica las principales bases de datos y estrategias de búsqueda, incluyendo el modelo PICO. Detalla los pasos para formular una pregunta de investigación, seleccionar palabras clave apropiadas y utilizar operadores lógicos para obtener resultados relevantes. Además, enfatiza la importancia de documentar la búsqueda realizada.
El documento habla sobre los fundamentos y metodología de la investigación cuantitativa. Explica los diferentes tipos de diseños de investigación como descriptivos, correlacionales y experimentales. También cubre temas como tipos de muestreo, métodos de recogida de datos, análisis estadístico y consideraciones éticas.
Cuestiones prácticas en la administración de fármacos: técnicas de dilución, formas de preparación, estabilidad. Curso impartido a enfermería por el Departamento de Farmacología de la Clinica Universidad de Navarra.
Estrategias de afrontamiento ante el maltrato verbal y conductual al personal de enfermeria. Curso impartido para enfermería de la Clínica Universidad de Navarra
Este documento resume las novedades en reanimación cardiopulmonar avanzada de 2010, incluyendo énfasis en compresiones torácicas continuas y de alta calidad, desfibrilación precoz, uso de adrenalina y amiodarona, y tratamiento post-reanimación como hipotermia terapéutica. También cubre puntos clave como reconocimiento temprano de parada cardiaca, llamada al 500, relación compresión-ventilación de 30:2, y causas potencialmente reversibles como hipoxia, hipovolemia e hip
El documento describe la importancia de la educación sanitaria del paciente y su familia para mejorar la adherencia al tratamiento y la seguridad de la medicación. Explica que la educación del paciente debe proporcionar conocimientos sobre el nombre, indicaciones, dosis y efectos del medicamento, así como instrucciones sobre omisiones de dosis e interacciones con otros fármacos. También destaca la necesidad de evaluar factores como la accesibilidad del sistema de salud y la comunicación médico-paciente que pueden afectar a la adherencia.
Material didactico del curso "Diagnóstico de bacteriemia. Hemocultivos" que impartió el Servicio de Microbiología de la Clínica Universidad de Navarra.
Este documento resume los resultados de un estudio sobre los factores de riesgo asociados al fallo primario (precoz) del injerto tras un trasplante cardíaco. Algunos de los hallazgos principales son:
1) Los receptores con diabetes, requerimiento previo de inotrópicos y elevación de la presión pulmonar tenían un mayor riesgo de fallo primario del injerto.
2) Los donantes de mayor edad y sexo femenino también se asociaron con un mayor riesgo.
3) El tratamiento del fallo
El documento habla sobre la visión de la Organización Nacional de Trasplantes de España respecto al trasplante cardiaco y la donación de órganos. La ONT promueve una estrategia de autosuficiencia en la que cada país debe esforzarse por satisfacer las necesidades de sus pacientes mediante la obtención de recursos dentro del propio país y la cooperación regional o internacional regulada cuando sea necesario.
El documento discute los límites en el trasplante cardiaco. Señala que la edad mayor de 70 años, afecciones sistémicas como diabetes o miopatías, y arteriopatía periférica severa son indicaciones límite comúnmente aceptadas. Analiza la supervivencia del trasplante según grupos de edad y encuentra que aunque disminuye con la edad, la supervivencia a los 70 años sigue siendo alta. Finalmente, argumenta que el uso de donantes marginales puede expandir la oferta y reducir los tiempos de espera
This document discusses surgical treatment of atrial fibrillation, specifically left atrial isolation surgery. It provides an overview of the techniques, clinical issues, and results of surgical ablation studies. Surgical ablation has been shown to have better outcomes than percutaneous approaches in eliminating atrial fibrillation and reducing thromboembolic events. Removing the left atrial appendage surgically may further reduce embolic risk compared to rate or rhythm control alone by eliminating the main site of clot formation.
Pharmacotherapy of Asthma and Chronic Obstructive Pulmonary Disease (COPD)HRITHIK DEY
This PowerPoint presentation provides an in-depth overview of the pharmacotherapy approaches for managing asthma and Chronic Obstructive Pulmonary Disease (COPD). It covers the pathophysiology of these respiratory conditions, the various classes of medications used, their mechanisms of action, indications, side effects, and the latest treatment guidelines. Designed for students, healthcare professionals, and anyone interested in respiratory pharmacology, this presentation offers a comprehensive understanding of current therapeutic strategies and advancements in the field.
A comparative study on uroculturome antimicrobial susceptibility in apparentl...Bhoj Raj Singh
The uroculturome indicates the profile of culturable microbes inhabiting the urinary tract, and it is often required to do a urine culture to find an effective antimicrobial to treat UTIs. This study targeted to understand the profile of culturable pathogens in the urine of apparently healthy (128) and humans with clinical UTIs (161). In urine samples from UTI cases, microbial counts were 1.2×104 ± 6.02×103 colony-forming units (cfu)/ mL, while in urine samples from apparently healthy humans, the average count was 3.33± 1.34×103 cfu/ mL. In eight samples (six from UTI cases and two from apparently healthy people) of urine, Candida (C. albicans 3, C. catenulata 1, C. krusei 1, C. tropicalis 1, C. parapsiplosis 1, C. gulliermondii 1) and Rhizopus species (1) were detected. Candida krusei was detected only in a single urine sample from a healthy person and C. albicans was detected both in urine of healthy and clinical UTI cases. Fungal strains were always detected with one or more types of bacteria. Gram-positive bacteria were more commonly (OR, 1.98; CI99, 1.01-3.87) detected in urine samples of apparently healthy humans, and Gram -ve bacteria (OR, 2.74; CI99, 1.44-5.23) in urines of UTI cases. From urine samples of 161 UTI cases, a total of 90 different types of microbes were detected and, 73 samples had only a single type of bacteria. In contrast, 49, 29, 3, 4, 1, and 2 samples had 2, 3, 4, 5, 6 and 7 types of bacteria, respectively. The most common bacteria detected in urine of UTI cases was Escherichia coli detected in 52 samples, in 20 cases as the single type of bacteria, other 34 types of bacteria were detected in pure form in 53 cases. From 128 urine samples of apparently healthy people, 88 types of microbes were detected either singly or in association with others, from 64 urine samples only a single type of bacteria was detected while 34, 13, 3, 11, 2 and 1 samples yielded 2, 3, 4, 5, 6 and seven types of microbes, respectively. In the urine of apparently healthy humans too, E. coli was the most common bacteria, detected in pure culture from 10 samples followed by Staphylococcus haemolyticus (9), S. intermedius (5), and S. aureus (5), and similar types of bacteria also dominated in cases of mixed occurrence, E. coli was detected in 26, S. aureus in 22 and S. haemolyticus in 19 urine samples, respectively. Gram +ve bacteria isolated from urine samples' irrespective of health status were more often (p, <0.01) resistant than Gram -ve bacteria to ajowan oil, holy basil oil, cinnamaldehyde, and cinnamon oil, but more susceptible to sandalwood oil (p, <0.01). However, for antibiotics, Gram +ve were more often susceptible than Gram -ve bacteria to cephalosporins, doxycycline, and nitrofurantoin. The study concludes that to understand the role of good and bad bacteria in the urinary tract microbiome more targeted studies are needed to discern the isolates at the pathotype level.
Chair, Benjamin M. Greenberg, MD, MHS, discusses neuromyelitis optica spectrum disorder in this CME activity titled “Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/4av12w4. CME credit will be available until June 27, 2025.
Chemical kinetics is the study of the rates at which chemical reactions occur and the factors that influence these rates.
Importance in Pharmaceuticals: Understanding chemical kinetics is essential for predicting the shelf life of drugs, optimizing storage conditions, and ensuring consistent drug performance.
Rate of Reaction: The speed at which reactants are converted to products.
Factors Influencing Reaction Rates:
Concentration of Reactants: Higher concentrations generally increase the rate of reaction.
Temperature: Increasing temperature typically increases reaction rates.
Catalysts: Substances that increase the reaction rate without being consumed in the process.
Physical State of Reactants: The surface area and physical state (solid, liquid, gas) of reactants can affect the reaction rate.
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.GawadNephroTube - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/pCU7Plqbo-E
- Video recording of this lecture in Arabic language: https://youtu.be/kbDs1uaeyyo
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Ventilation Perfusion Ratio, Physiological dead space and physiological shuntMedicoseAcademics
In this insightful lecture, Dr. Faiza, an esteemed Assistant Professor of Physiology, delves into the essential concept of the ventilation-perfusion ratio (V˙/Q˙), which is fundamental to understanding pulmonary physiology. Dr. Faiza brings a wealth of knowledge and experience to the table, with qualifications including MBBS, FCPS in Physiology, and multiple postgraduate degrees in public health and healthcare education.
The lecture begins by laying the groundwork with basic concepts, explaining the definitions of ventilation (V˙) and perfusion (Q˙), and highlighting the significance of the ventilation-perfusion ratio (V˙/Q˙). Dr. Faiza explains the normal value of this ratio and its critical role in ensuring efficient gas exchange in the lungs.
Next, the discussion moves to the impact of different V˙/Q˙ ratios on alveolar gas concentrations. Participants will learn how a normal, zero, or infinite V˙/Q˙ ratio affects the partial pressures of oxygen and carbon dioxide in the alveoli. Dr. Faiza provides a detailed comparison of alveolar gas concentrations in these varying scenarios, offering a clear understanding of the physiological changes that occur.
The lecture also covers the concepts of physiological shunt and dead space. Dr. Faiza defines physiological shunt and explains its causes and effects on gas exchange, distinguishing it from anatomical dead space. She also discusses physiological dead space in detail, including how it is calculated using the Bohr equation. The components and significance of the Bohr equation are thoroughly explained, and practical examples of its application are provided.
Further, the lecture examines the variations in V˙/Q˙ ratios in different regions of the lung and under different conditions, such as lying versus supine and resting versus exercise. Dr. Faiza analyzes how these variations affect pulmonary function and discusses the abnormal V˙/Q˙ ratios seen in chronic obstructive lung disease (COPD) and their clinical implications.
Finally, Dr. Faiza explores the clinical implications of abnormal V˙/Q˙ ratios. She identifies clinical conditions associated with these abnormalities, such as COPD and emphysema, and discusses the physiological and clinical consequences on respiratory function. The lecture emphasizes the importance of understanding these concepts for medical professionals and students, highlighting their relevance in diagnosing and managing respiratory conditions.
This comprehensive lecture provides valuable insights for medical students, healthcare professionals, and anyone interested in respiratory physiology. Participants will gain a deep understanding of how ventilation and perfusion work together to optimize gas exchange in the lungs and how deviations from the norm can lead to significant clinical issues.
Join the leading All Range PCD Pharma Franchise in India and grow your business with a trusted partner. We offer an extensive range of high-quality pharmaceutical products, competitive pricing, and comprehensive marketing support. Benefit from our expertise, wide distribution network, and excellent customer service. Elevate your pharma business with See Ever Healthcare's proven PCD franchise model.
https://www.seeeverhealthcare.com/all-range-pcd-pharma-franchise-in-india/
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptxFFragrant
Not all women with hydrosalpinx should choose laparoscopy. Natural medicine Fuyan Pill can also be a nice option for patients, especially when they have fertility needs.
Why Does Seminal Vesiculitis Causes Jelly-like Sperm.pptxAmandaChou9
Seminal vesiculitis can cause jelly-like sperm. Fortunately, herbal medicine Diuretic and Anti-inflammatory Pill can eliminate symptoms and cure the disease.
Chair and Presenter, Stephen V. Liu, MD, Benjamin Levy, MD, Jessica J. Lin, MD, and Prof. Solange Peters, MD, PhD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/NCPD/AAPA/IPCE activity titled “Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/4bBb8fi. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.
Descoperă Bucuria Vieții Sănătoase cu Jurnalul Fericirii Life Care - Iulie 2024!
Gata să te bucuri de o vară vibrantă și plină de energie? Life Care îți vine în ajutor cu Jurnalul Fericirii din Iulie 2024, un ghid complet pentru o viață armonioasă și echilibrată.
Pe parcursul a cateva de pagini pline de informații utile și inspirație, vei descoperi:
Sfaturi practice pentru o alimentație sănătoasă:
Rețete delicioase și ușor de preparat: Bucură-te de preparate gustoase și nutritive, perfecte pentru zilele călduroase de vară.
Recomandări pentru o alimentație echilibrată: Asigură-ți aportul necesar de nutrienți esențiali pentru un organism sănătos și plin de vitalitate.
Sfaturi pentru alegeri alimentare inteligente: Învață cum să faci cumpărături sănătoase și să eviți tentațiile nesănătoase.
Trucuri pentru un stil de viață activ:
Rutine de exerciții fizice adaptate nevoilor tale: Găsește antrenamente potrivite pentru a te menține în formă și energic pe tot parcursul verii.
Idei de activități în aer liber: Descoperă modalități distractive de a te bucura de vremea frumoasă și de a petrece timp de calitate cu cei dragi.
Sfaturi pentru un somn odihnitor: Asigură-ți un somn profund și reparator pentru a te trezi revigorat și pregătit pentru o nouă zi.
Sfaturi pentru o stare de bine mentală:
Tehnici de relaxare și gestionare a stresului: Învață cum să te relaxezi și să faci față provocărilor zilnice cu mai multă ușurință.
Sfaturi pentru cultivarea optimismului și a gândirii pozitive: Descoperă cum să abordezi viața cu o perspectivă optimistă și să atragi mai multă bucurie în ea.
Recomandări pentru a te conecta cu natura: Bucură-te de beneficiile naturii asupra stării tale mentale și emoționale.
Bonus:
Oferte exclusive la produsele Life Care: Beneficiază de reduceri și promoții speciale la o gamă largă de produse pentru o viață sănătoasă.
Concursuri și premii: Participă la concursuri distractive și câștigă premii valoroase.
Jurnalul Fericirii Life Care - Iulie 2024 este mai mult decât o simplă revistă. Este un ghid complet și personalizat pentru a te ajuta să obții o viață mai sănătoasă, mai fericită și mai plină de satisfacții.
Nu rata această șansă de a te bucura de vară la maximum! Descoperă Jurnalul Fericirii Life Care - Iulie 2024 astăzi!
Comandă-ți exemplarul acum și fă un pas important către o viață mai bună!
#JurnalulFericirii #LifeCare #Iulie2024 #ViataSanatoasa #Bunastare #Fericire #Oferte #Concursuri #Premii
9. ¢ ELSO registry from 1986–2006
¢ 1,473 patients with severe respiratory
failure
l 50% survived to hospital discharge
¢ Median age was 34 years.
¢ Most patients (78%) supported with
venovenous ECMO
10. ¢ Multivariate logistic regression model
¢ Pre-ECMO factors associated with increased
odds of death were
l Increasing age
l Decreased weight
l Days on mechanical ventilation before ECMO
l Arterial blood pH < 7.18
l Hispanic and Asian race vs. white race
l ECMO VA vs. ECMO VV
26. ¢ UK, 2001-2006
¢ ECMO provided only at the Glenfield
Hospital, Leicester
¢ Entry criteria:
l Adult patients (18-65 years)
l Severe, but potentially reversible ARDS
l Murray score ≥3.0, or
l Uncompensated hypercapnia: pH <7.20
The CESAR trial
27. ¢ Primary outcome measure
l Death or severe disability 6 months
l Severe disability defined as being both
"confined to bed" and "unable to wash
or dress oneself“
¢ Secondary outcomes
l Death at 6 months, at hospital
discharge
l HRQL, costs…
31. ¢ Time from
randomization
to death
¢ Log rank
p = 0.03
32. ECMO : potential indications
• Refractory hypoxemia: PaO2/FiO2 < 50, persistent *
Despite: FiO2 > 80 %, PEEP (≤ 20 cmH2O)
targeting Pplat = 32 cmH2O, prone position +/- NOi
• Plateau Pressure ≥ 35 cmH2O
despite reducing PEEP to 5 cmH2O
AND reducing Vt to 4 ml/kg providing that pH ≥ 7,15
* : Should also account for disease’s type and evolution
33. Where to perform ECMO?
• Experienced centers:
• With Heart surgeons, intensivists, perfusionists, nurses….
• All experienced in the management of ECMO devices
• ECMO programs should include a
mobile ECMO retrieval team
• Available 24H/7D
• Nationwide or regional EMCO networks necessary
34. ECMO configuration for
acute respiratory failure
Should always be venovenous…
…Except in the case of severe
associated cardiogenic shock
35. Peripheral VA ECMO is not
indicated for ARF because…
¢ Flow competition in the aorta
l Heart vs. ECMO pump
¢ If pulmonary function is impaired
l The “Harlequin” syndrome
• “Blue head”: deoxygenated blood directed
to the upper part of the body
• “Red legs”: hyperoxygenated blood in the
lower part of the body
¢ Not possible to rest the lungs
l Vt, Pplat and FiO2 cannot be reduced
36. Peripheral VA ECMO is not
indicated for ARF because…
¢ VA ECMO increases LV afterload
l Risk of myocardial damage/stunning
¢ Complications associated with the
arterial line in VA femoro-femoral ECMO
l Leg ischemia
l Arterial embolism
l Massive arterial hemorrhage
38. Blood oxygenation objectives
in VV ECMO
¢ SaO2 >86-88%
¢ May be difficult to obtain more…
l Because of blood recirculation
l Even if FiO2 set at 100% on the
machine
¢ CO2 elimination much easier
39. RECIRCULATION:
The major limitation of VV ECMO
¢ Factors increasing Recirculation
l Proximity of venous catheter tips
l Low cardiac output
l Hypovolemia and decreased RA
blood content
l Increased pump flow
40. How to optimize blood oxygenation?
¢ Minimize recirculation
l Cannulas adequately (re)positionned
l Fluid loading to correct hypovolemia
l Adjust pump flow
¢ ECMO flow objective:
l Pump flow: the major determinant of oxygenation
• >5 - 6 l/min or >3 L/m² or >70% of CO
l USE LARGE DRAINAGE CANNULAS!!!
¢ Other parameters
l Red cells transfusion: Hb >10 g/dl
45. Conclusion
¢ For the most severe forms of acute respiratory
failure, ECMO:
l Replaces pulmonary function
l Allows ultraprotective MV settings
l Should allow facilitated lung healing
¢ Only experienced centers should run these programs
l With a mobile ECMO retrieval team available 24H/7D
¢ Still a controversy on the use of ECMO
l Need for a confirmation trial
46. La Pitié: Louis XIX, 1656…
To 2010…
La Chapelle Institut de Cardiologie
48. EOLIA: ECMO to rescue Lung Injury
in severe ARDS
¢ Multicenter international randomized controlled trial
¢ Best care possible in the ECMO arm
l ECMO initiated asap for every patient randomized
• Using the most recent ECMO technology
• CardioHelp, from Maquet
l Inclusion of some non-ECMO centers with a mobile
ECMO rescue team available from the referral center
in less than 1 hour
• Transport of randomized patients to the referral center
UNDER ECMO
• ECMO managed only in highly experienced centers
l “Highly protective” MV
• Plateau pressure limited to ≤ 20 cm H2O
49. EOLIA: ECMO to rescue Lung Injury
in severe ARDS
¢ Best care possible in the control arm
l MV protocolized using the
“high PEEP – high recruitment” strategy of
the EXPRESS trial
l To limit plateau pressure <28-30 cm H2O
• Vt limited to 6 ml/kg IBW
l “Ethical” cross-over option to ECMO if the
patient develops refractory hypoxemia